Considerations for Child Cancer Survivors and Immunocompromised Children to Prevent Secondary HPV-associated Cancers.
Age Factors
Alphapapillomavirus
/ immunology
Cancer Survivors
Host-Pathogen Interactions
Humans
Immunocompromised Host
Immunogenicity, Vaccine
Neoplasms, Second Primary
/ immunology
Papillomavirus Infections
/ immunology
Papillomavirus Vaccines
/ adverse effects
Risk Assessment
Risk Factors
Time Factors
Vaccination
Virus Activation
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
pubmed:
6
9
2020
medline:
27
7
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Survivors of childhood cancer and other immunocompromised children are at high risk for the development of secondary human papillomavirus (HPV)-associated cancers. In this overview, the authors examine the epidemiology of vaccine efficacy, the natural history of HPV infections, and accelerated HPV-associated cancer development in these populations. The authors highlight the opportunities for preventive care and future research directives.
Identifiants
pubmed: 32890137
pii: 00007890-202104000-00013
doi: 10.1097/TP.0000000000003444
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
736-742Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I InvestigatorsQuadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356191928–1943
Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 155565–580
Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018; 5:CD009069
Markowitz LE, Naleway AL, Lewis RM, et al. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: evidence of direct and herd effects of vaccination. Vaccine. 2019; 37293918–3924
Drolet M, Bénard É, Pérez N, et al. HPV Vaccination Impact Study GroupPopulation-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 39410197497–509
Lehtinen M, Paavonen J, Wheeler CM, et al. HPV PATRICIA Study GroupOverall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13189–99
McClung NM, Gargano JW, Park IU, et al. Estimated number of cases of high-grade cervical lesions diagnosed among women—United States, 2008 and 2016. Morb Mortal W kly Rep. 2019; 6815337–343
Wilkin TJ, Chen H, Cespedes MS, et al. A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018; 6791339–1346
Kahn JA, Xu J, Kapogiannis BG, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013; 575735–744
Kojic EM, Kang M, Cespedes MS, et al. Immunogenicity and safety of the quadrivalent human Papillomavirus vaccine in HIV-1–infected women. Clin Infect Dis. 2014; 591135–127
Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365171576–1585
Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010; 20281246–1253
Gravitt P, Winer R.Natural history of HPV infection across the lifespan: role of viral latency. Viruses. 2017; 910267
Gravitt PE.The known unknowns of HPV natural history. J Clin Invest. 2011; 121124593–4599
Gravitt PE.Evidence and impact of human papillomavirus latency. Open Virol J. 2012; 6:198–203
de Sanjosé S, Brotons M, Pavón MA.The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018; 47:2–13
Theiler RN, Farr SL, Karon JM, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol. 2010; 11561150–1158
Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005; 978577–586
Moscicki AB, Karalius B, Tassiopoulos K, et al. Pediatric HIV/AIDS Cohort StudyHuman papillomavirus antibody levels and quadrivalent vaccine clinical effectiveness in perinatally human immunodeficiency virus-infected and exposed, uninfected youth. Clin Infect Dis. 2019; 6971183–1191
Maglennon GA, McIntosh PB, Doorbar J.Immunosuppression facilitates the reactivation of latent papillomavirus infections. J Virol. 2014; 881710–716
Lin R, Liu Q.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2013; 6:94
van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT. Blood. 2001; 984972–978
Ermel A, Shew ML, Imburgia TM, et al. Redetection of human papillomavirus type 16 infections of the cervix in mid-adult life. Papillomavirus Res. 2018; 5:75–79
van Schalkwyk C, Moodley J, Welte A, et al. Estimated impact of human papillomavirus vaccines on infection burden: The effect of structural assumptions. Vaccine. 2019; 37365460–5465
Rosillon D, Baril L, Del Rosario-Raymundo MR, et al. Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies. Cancer Med. 2019; 8104938–4953
Twisk DE, van der Sande MAB, van Eeden A, et al. Detection of incident anal men who have sex with men: incidence or reactivationhigh-risk human papillomavirus DNA in. J Infect Dis. 2018; 21871018–1026
Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001; 192464–471
Savani BN, Stratton P, Shenoy A, et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation–implications for screening and HPV vaccination. Biol Blood Marrow Transplant. 2008; 1491072–1075
Wang Y, Brinch L, Jebsen P, et al. A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 185747–753
Nassiri N, Eslani M, Panahi N, et al. Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations. J Ophthalmic Vis Res. 2013; 84351–358
Sri T, Merideth MA, Pulanic TK, et al. Human papillomavirus reactivation following treatment of genital graft-versus-host disease. Transpl Infect Dis. 2013; 154E148–E151
Buchan A, Merideth MA, Childs RW, et al. Novel management of vaginal chronic graft-versus-host disease causing haematometra and haematocolpos. BMJ Case Rep. 2018; 2018:bcr-2017-222720
Pereira CM, Melo LG, Correa MM, et al. Oral HPV infection in a bone marrow transplantation patient: a case report with atypical clinical presentation and unexpected outcome. Braz J Infect Dis. 2010; 14189–91
Shew ML, Ermel AC, Weaver BA, et al. Association of Chlamydia trachomatis infection with redetection of human papillomavirus after apparent clearance. J Infect Dis. 2013; 20891416–1421
Liao JB, Fisher CE, Madeleine MM.Gynecologic cancers and solid organ transplantation. Am J Transplant. 2019; 1951266–1277
Hinten F, Meeuwis K, Van Rossum M, et al. HPV-related (pre) malignancies of the female anogenital tract in renal transplant recipients. Crit Rev Oncol/Hematol. 2012; 842161–180
Madeleine MM, Finch JL, Lynch CF, et al. HPV-related cancers after solid organ transplantation in the United States. Am J Transplant. 2013; 13123202–3209
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306171891–1901
Meeuwis KA, van Rossum MM, Hoitsma AJ, et al. (Pre)malignancies of the female anogenital tract in renal transplant recipients. Transplantation. 2011; 9118–10
Hinten F, Hilbrands LB, Meeuwis KAP, et al. Reactivation of latent HPV infections after renal transplantation. Am J Transplant. 2017; 1761563–1573
Meeuwis KA, Hilbrands LB, IntHout J, et al. Cervicovaginal HPV infection in female renal transplant recipients: an observational, self-sampling based, cohort study. Am J Transplant. 2015; 153723–733
Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370958159–67
Dugué PA, Rebolj M, Garred P, et al. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther. 2013; 13129–42
Fife KH, Katz BP, Roush J, et al. Cancer-associated human papillomavirus types are selectively increased in the cervix of women in the first trimester of pregnancy. Am J Obstet Gynecol. 1996; 17451487–1493
Siddiqui G, Kurzel RB, Lampley EC, et al. Cervical dysplasia in pregnancy: progression versus regression post-partum. Int J Fertil Womens Med. 2001; 465278–280
Hernández-Girón C, Smith JS, Lorincz A, et al. High-risk human papillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico. Sex Transm Dis. 2005; 3210613–618
Liu G, Sharma M, Tan N, et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018; 326795–808
Levin MJ, Moscicki A-B, Song L-Y, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010; 552197–204
Rotstein Grein IH, Pinto NF, Lobo A, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study. Lupus. 2020; 298934–942
Athanasiou A, Bowden S, Paraskevaidi M, et al. HPV vaccination and cancer prevention. Best Pract Res Clin Obstet Gynaecol. 2020; 65:109–124
Lin A, Ong KJ, Hobbelen P, et al. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis. 2017; 645580–588
Garland SM, Brotherton JML, Moscicki AB, et al. IPVSHPV vaccination of immunocompromised hosts. Papillomavirus Res. 2017; 4:35–38
Stratton P, Battiwalla M, Tian X, et al. Immune response following quadrivalent human papillomavirus vaccination in women after hematopoietic allogeneic stem cell transplant: a nonrandomized clinical trial. JAMA Oncol. 2020; 651–10
Nailescu C, Nelson RD, Verghese PS, et al. Human Papillomavirus Vaccination in Male and Female Adolescents Before and After Kidney Transplantation: A Pediatric Nephrology Research Consortium Study. Front Pediatr. 2020; 8:46
Ojha RP, Tota JE, Offutt-Powell TN, et al. Human papillomavirus-associated subsequent malignancies among long-term survivors of pediatric and young adult cancers. PLoS One. 2013; 88e70349
Castellino SM, Allen KE, Pleasant K, et al. Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer. J Cancer Surviv. 2019; 135730–738
Klosky JL, Hudson MM, Chen Y, et al. Human papillomavirus (HPV) vaccination among survivors of childhood cancer: predictors of non-initiation and population comparisons. J Clin Oncol. 2016; 3415_suppl10573
Children’s Oncology GroupLong-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 3.0 2008. Available at http://www.survivorshipguidelines.org/pdf/COG%20LTFU%20Guidelines%20Archive/Version%203.0/COG_LTFU_Guidelines_v3%20(secured).pdf Accessed July 24, 2019
Ford JS, Kawashima T, Whitton J, et al. Psychosexual functioning among adult female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2014; 32283126–3136
Zebrack BJ, Casillas J, Nohr L, et al. Fertility issues for young adult survivors of childhood cancer. Psychooncology. 2004; 1310689–699
Klosky JL, Howell CR, Li Z, et al. Risky health behavior among adolescents in the childhood cancer survivor study cohort. J Pediatr Psychol. 2012; 376634–646
Yeazel MW, Oeffinger KC, Gurney JG, et al. The cancer screening practices of adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2004; 1003631–640
Tirri BF, Häusermann P, Bertz H, et al. Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD. Bone Marrow Transplant. 2015; 5013–9
Ljungman P, Cordonnier C, Einsele H, et al. Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and PreventionVaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009; 448521–526
Hwang JP.Gardasil 9 vaccine in preventing HPV infection in patients with hematologic malignancies undergoing donor stem cell transplant. 2017, M D Anderson Cancer Center. Available at https://ClinicalTrials.gov/show/NCT03023631 . Accessed June 6, 2019
Kumar D, Unger ER, Panicker G, et al. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant. 2013; 1392411–2417
Chin-Hong P, Reid G. AST Infectious Diseases Community of Practice. Human papillomavirus infection in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33:e13590
Feldman AG, Hsu EK, Mack CL.The importance of prioritizing pre and posttransplant immunizations in an era of vaccine refusal and epidemic outbreaks. Transplantation. 2020; 104133–38
Klosky JL, Favaro B, Peck KR, et al. Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer. J Cancer Surviv. 2016; 103449–456
Moscicki AB, Flowers L, Huchko MJ, et al. Guidelines for cervical cancer screening in immunosuppressed women without hiv infection. J Low Genit Tract Dis. 2019; 23287–101
Dantal J, Campone M.Daunting but worthy goal: reducing the De Novo cancer incidence after transplantation. Transplantation. 2016; 100122569–2583
Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. Am J Transplant. 2019; 19113202–3206